Lilly, Sanofi, Novo among many pharma players to throw off big price gains in H1

Eric Palmer

The first half of the year has provided a good ride for Big and its investors with indices up in the U.S. and Europe. Even Japanese drugmakers avoided the side effects of China's stock market meltdown and saw values rise 23%. But, of course, averages come from the highs and the lows and some have actually seen share declines during this bull market.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS